Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice

Show simple item record Guo, Jianfeng Ogier, Julien R. Desgranges, Stephane O'Driscoll, Caitríona M. Darcy, Raphael 2013-01-22T13:32:04Z 2013-01-22T13:32:04Z 2012 2012-11
dc.identifier.citation Guo J., Ogier J., Desgranges S., Darcy R., and O Driscoll CM. (2012) 'Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice'. Biomaterials, 33 (31):7775-7784. en
dc.identifier.volume 33 en
dc.identifier.issued 31 en
dc.identifier.startpage 7775 en
dc.identifier.endpage 7784 en
dc.identifier.issn 0142-9612
dc.identifier.doi 10.1016/j.biomaterials.2012.07.012
dc.description.abstract A hepta-guanidino-β-cyclodextrin (G-CD), its hepta-PEG conjugate (G-CD-PEG), and the corresponding anisamide-terminated PEG conjugate (G-CD-PEG-AA) have been synthesised and compared as delivery vectors for siRNA to prostate cancer cells and tumours in vivo. The G-CD-PEG-AA.siRNA formulations (in which anisamide targets the sigma receptor), but not the non-targeted formulations, induced prostate cell-specific internalisation of siRNA resulting in approximately 80% knockdown in vitro of the reporter gene, luciferase. Following intravenous administration of the anisamide-targeted formulation in a mouse prostate tumour model significant tumour inactivation with corresponding reductions in the level of vascular endothelial growth factor (VEGF) mRNA were achieved, without demonstrating enhanced toxicity. This data imply significant potential for anisamide-conjugated cyclodextrin vectors for targeted delivery of therapeutic siRNAs in the treatment of prostate cancer. en
dc.description.sponsorship Irish Research Council for Science, Engineering and Technology (EMBARK initiative); Science Foundation Ireland (via a Strategic Research Cluster Grant (Irish Drug Delivery Network)); Enterprise Ireland (a Commercial Fund Technology Development Grant) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Elsevier en
dc.rights Copyright © 2012, Elsevier. NOTICE: this is the author’s version of a work that was accepted for publication in Biomaterials. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Biomaterials, [33, November 2012] en
dc.subject Cyclodextrin en
dc.subject siRNA en
dc.subject Non-viral vector en
dc.subject Pegylation en
dc.subject Anisamide en
dc.subject Sigma receptor en
dc.subject RNAi en
dc.subject Prostate cancer en
dc.subject.lcsh Prostate--Cancer--Treatment en
dc.title Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice en
dc.type Article (peer-reviewed) en
dc.internal.authorurl en
dc.internal.authorcontactother Caitriona O'Driscoll, School Of Pharmacy, University College Cork, Cork, Ireland. +353-21-490-3000 Email: en
dc.internal.availability Full text available en 2013-01-17T10:44:30Z
dc.description.version Accepted Version en
dc.internal.rssid 181751439
dc.contributor.funder Irish Research Council for Science Engineering and Technology en
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Enterprise Ireland en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Biomaterials en
dc.internal.copyrightchecked No. !!CORA - ROMEO. Elsevier policy - accepted manuscript and set statement en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress en

Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement